Fisher Asset Management
PCRX icon

Fisher Asset Management’s Pacira BioSciences PCRX Stock Holding History

Fisher Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-12,428
Closed -$498K – 1238
2023
Q2 		$498K Hold
12,428
– – ﹤0.01% 868
2023
Q1 		$507K Sell
12,428
-8,430
-40% -$335K ﹤0.01% 848
2022
Q4 		$805K Buy
20,858
+54
+0.3% +$2.63K ﹤0.01% 794
2022
Q3 		$1.11M Hold
20,804
– – ﹤0.01% 651
2022
Q2 		$1.21M Buy
20,804
+85
+0.4% +$5.57K ﹤0.01% 602
2022
Q1 		$1.58M Hold
20,719
– – ﹤0.01% 581
2021
Q4 		$1.25M Sell
20,719
-68
-0.3% -$3.75K ﹤0.01% 611
2021
Q3 		$1.16M Buy
20,787
+4,847
+30% +$279K ﹤0.01% 595
2021
Q2 		$967K Sell
15,940
-10
-0.1% -$633 ﹤0.01% 622
2021
Q1 		$1.12M Sell
15,950
-1,582
-9% -$113K ﹤0.01% 599
2020
Q4 		$1.05M Buy
17,532
+1,948
+13% +$114K ﹤0.01% 591
2020
Q3 		$937K Sell
15,584
-6,968
-31% -$405K ﹤0.01% 570
2020
Q2 		$1.18M Sell
22,552
-3,565
-14% -$149K ﹤0.01% 549
2020
Q1 		$876K Sell
26,117
-79
-0.3% -$3.28K ﹤0.01% 552
2019
Q4 		$1.19M Sell
26,196
-4,508
-15% -$191K ﹤0.01% 565
2019
Q3 		$1.17M Buy
+30,704
New +$1.23M ﹤0.01% 601
2018
Q1 		– Sell
-5,282
Closed -$241K – 812
2017
Q4 		$241K Buy
+5,282
New +$209K ﹤0.01% 782
2017
Q3 		– Sell
-6,257
Closed -$298K – 811
2017
Q2 		$298K Hold
6,257
– – ﹤0.01% 653
2017
Q1 		$285K Buy
+6,257
New +$270K ﹤0.01% 635
2016
Q4 		– Sell
-6,282
Closed -$215K – 749
2016
Q3 		$215K Buy
6,282
+85
+1% +$3.33K ﹤0.01% 677
2016
Q2 		$226K Hold
6,197
– – ﹤0.01% 647
2016
Q1 		$400K Hold
6,197
– – ﹤0.01% 584
2015
Q4 		$476K Buy
6,197
+247
+4% +$14K ﹤0.01% 577
2015
Q3 		$245K Buy
5,950
+1,150
+24% +$70.4K ﹤0.01% 612
2015
Q2 		$339K Hold
4,800
– – ﹤0.01% 494
2015
Q1 		$426K Hold
4,800
– – ﹤0.01% 459
2014
Q4 		$426K Buy
+4,800
New +$454K ﹤0.01% 463

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

Fisher Asset Management's PCRX Position: Q3 2023 in Review

Fisher Asset Management sold out of Pacira BioSciences (PCRX) in Q3 2023, closing a stake of 12,428 shares — an estimated $498K sold.

Fisher Asset Management first reported a position in PCRX in Q4 2014 and held it in 27 quarters. The position peaked at $1.58M in Q1 2022. 261 funds tracked by Wall St. Rank hold PCRX as of Q3 2023.

  • Fisher Asset Management reported no remaining Pacira BioSciences position as of Q3 2023 after selling out during the quarter.
  • Fisher Asset Management sold 12,428 Pacira BioSciences shares in Q3 2023, an estimated $498K.
  • Fisher Asset Management first reported a position in Pacira BioSciences in Q4 2014 and held it in 27 quarters.
  • Fisher Asset Management's Pacira BioSciences position peaked at $1.58M in Q1 2022.
  • 261 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2023.

Based on Fisher Asset Management's 13F filing for Q3 2023, filed 13 Nov 2023.